Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Diarrhea 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Colitis 1

Interventions

Paclitaxel 4pembrolizumab 3Cisplatin 3Doxorubicin 2Carboplatin 2Brachytherapy 2Biopsy 2trastuzumab deruxtecan 1sacituzumab govitecan 1relugolix 1dostarlimab 1dehydroftorafur 1belzutifan 1Watchful Waiting 1Vaginal Smears 1VMBP protocol 1Ultrasound, High-Intensity Focused, Transrectal 1Transurethral Resection of Prostate 1Taxes 1Sutures 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Pregnancy Tests 1Practice Guidelines as Topic 1Platinum 1Papanicolaou Test 1Oxaliplatin 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Neoplasms × Loperamide × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡